Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.55 |
| ▸ | HTR2C | P28335 | 5/20 | 0.55 |
| ▸ | HTR2B | P41595 | 4/20 | 0.55 |
| ▸ | AR | P10275 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564105 | 0.82 | MAOA (0.49) | HTR2AHTR2CHTR2BMAOATSHR | |
| SCHEMBL19411037 | 0.81 | HTR2A (0.40) | HTR2AHTR2CHTR2BARMAOA | |
| SCHEMBL6186362 | 0.79 | AR (0.51) | HTR2AHTR2CHTR2BARHTR6 | |
| SCHEMBL19410987 | 0.77 | AR (0.51) | HTR2AHTR2CHTR2BARDRD2 | |
| SCHEMBL13942395 | 0.77 | HTR2A (0.43) | HTR2AHTR2CHTR2BMAOATSHR | |
| SCHEMBL12420344 | 0.77 | HTR2A (0.43) | HTR2AHTR2CHTR2BMAOATSHR | |
| SCHEMBL1701913 | 0.76 | MAOA (0.54) | MAOADRD2DRD4 | |
| SCHEMBL22340168 | 0.76 | HTR2C (0.53) | HTR2AHTR2CHTR2BMAOATSHR | |
| SCHEMBL7368648 | 0.76 | AR (0.50) | ARMAOADRD2DRD4 | |
| SCHEMBL7079658 | 0.75 | AR (0.48) | HTR2AHTR2CHTR2BARDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612284-B | Substituted indoline derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-110691773-B | Substituted indoline derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110461831-B | Substituted indoline derivatives as inhibitors of dengue virus replication | 杨森制药公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220340522-A1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2022-10-27 | — | — | US | disclosed |
| EP-3630723-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11407715-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3436436-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3436436-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-1998052943-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998004289-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT2C ANTAGONIST AND A D2 ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048699-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0808312-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1997-11-26 | — | — | EP | disclosed |
| EP-0807104-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT 2C? RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997008167-A1 | 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996023769-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT2C RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996011929-A1 | BIHETEROARYL-CARBONYL AND CARBOXAMIDE DERIVATIVES WITH 5HT 2C/2B ANTAGONISTS ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885HTR2B 396/4885 |
| US-20220340522-A1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885HTR2B 396/4885 |
| US-11407715-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | HTR2A 155/4885HTR2C 187/4885HTR2B 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.